#1 Clinical Trials Search in Europe

Specific Nucleic Acid Sna-Ebv

A clinical trial is underway to assess the effectiveness of a drug containing Specific Nucleic Acid SNA-EBV in treating fatigue associated with Epstein-Barr Virus (EBV) infection. This randomized, placebo-controlled, double-blind study aims to compare the efficacy of 2LEBV® and 2LXFS® in reducing fatigue severity and other EBV-related symptoms in patients aged 12 and older. The trial will evaluate various aspects of fatigue, immune system responses, and overall patient well-being over a 12-month period.

Table of Contents

What is SPECIFIC NUCLEIC ACID SNA-EBV?

SPECIFIC NUCLEIC ACID SNA-EBV, also known as SNA-EBV or Specific Nucleic Acid – Epstein Barr Virus, is an investigational treatment being studied for its potential to help patients with Epstein-Barr Virus (EBV) infection[1]. It is part of a medication called 2LEBV, which contains several active ingredients including SNA-EBV.

Target Condition: Epstein-Barr Virus Infection

Epstein-Barr Virus (EBV) is a common virus that can cause various symptoms and health issues. When a person is infected with EBV, they may experience symptoms such as fatigue, fever, sore throat, and swollen lymph nodes. In some cases, the infection can lead to prolonged fatigue and other persistent symptoms[1].

Current Clinical Trial

A clinical trial is currently underway to evaluate the effectiveness of 2LEBV (which contains SNA-EBV) in treating fatigue associated with EBV infection. This study is described as a “Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LEBV® and 2LXFS® on asthenia in patients with an EBV infection”[1].

Key points about the trial:

  • It aims to compare the effectiveness of 2LEBV or a combination of 2LXFS/2LEBV against a placebo in reducing fatigue severity
  • The study will measure fatigue using a questionnaire called MFI-20
  • Other symptoms related to EBV infection will also be evaluated
  • The trial will assess changes in the immune system by looking at lymphocyte (a type of white blood cell) levels and antibodies

How SNA-EBV May Work

While the exact mechanism is not fully explained in the trial information, SNA-EBV is described as a “specific nucleic acid.” Nucleic acids are important biological molecules that include DNA and RNA. In this case, SNA-EBV may be designed to target specific aspects of the Epstein-Barr Virus or help the immune system respond to the virus more effectively[1].

Potential Benefits

The main goal of using SNA-EBV (as part of 2LEBV) is to reduce fatigue in patients with EBV infection. The clinical trial is also looking at other potential benefits, including[1]:

  • Improvement in other EBV-related symptoms
  • Changes in the immune system response
  • Long-term effects on fatigue and other symptoms (up to 12 months after treatment)

How SNA-EBV is Administered

SNA-EBV is part of a medication called 2LEBV, which comes in the form of granules in capsules that are meant to be opened. The medication is administered through oromucosal use, which means it’s applied to the mucous membrane of the mouth[1].

Who Might Be Eligible for Treatment?

Based on the clinical trial criteria, potential candidates for this treatment include[1]:

  • Patients aged 12 years and older
  • Those experiencing significant fatigue for 1 month or more
  • Individuals with at least two other symptoms related to EBV infection
  • Patients with a positive EBV serology (blood test showing evidence of EBV infection)

Safety Considerations

As with any medical treatment, safety is an important consideration. The clinical trial is monitoring for any adverse events or side effects that may occur during treatment. It’s important to note that this is still an investigational treatment, and more research is needed to fully understand its safety profile and effectiveness[1].

Aspect Details
Study Type Randomized, placebo-controlled, double-blind clinical trial
Main Objective Evaluate efficacy of 2LEBV® and 2LXFS® on fatigue severity in EBV-infected patients
Primary Endpoint General fatigue scale of MFI-20 questionnaire at 6 months
Secondary Endpoints Other fatigue dimensions, EBV-related symptoms, lymphocyte typing, IgG levels, safety
Study Duration 12 months with assessments at 3, 6, and 12 months
Key Inclusion Criteria Age ≥12, significant fatigue for ≥1 month, ≥2 other EBV-related symptoms, positive EBV serology
Key Exclusion Criteria Recent homeopathic treatments, immunosuppressive therapy, psychiatric treatments
Active Substance Specific Nucleic Acid SNA-EBV, along with other nucleic acids and interleukins

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this trial is to compare the effectiveness of 2LEBV® or 2LXFS®/2LEBV® treatment versus a placebo in reducing fatigue severity in patients with Epstein-Barr Virus (EBV) infection at the end of the treatment period.
  • Who can participate in this clinical trial? Participants must be 12 years or older, experiencing significant fatigue for at least one month, have at least two other EBV-related symptoms, and test positive for EBV antibodies. However, there are several exclusion criteria, such as recent use of certain treatments or having specific medical conditions.
  • What will be measured during the trial? The trial will measure fatigue severity using the MFI-20 questionnaire, assess other EBV-related symptoms, analyze changes in lymphocyte typing and immune status, and monitor IgG antibody levels. Safety will also be evaluated by tracking adverse events.
  • How long does the trial last? The trial lasts for 12 months, with key assessments at 3 months (V3), 6 months (V4, end of treatment), and 12 months (V5) after the start of the study.
  • What is Specific Nucleic Acid SNA-EBV? Specific Nucleic Acid SNA-EBV is one of the active substances in the study drug 2LEBV®. It is a type of nucleic acid specifically designed to target the Epstein-Barr Virus. The drug also contains other substances like DNA, RNA, interleukins, and another specific nucleic acid targeting HLA II.

Ongoing Clinical Trials on Specific Nucleic Acid Sna-Ebv

  • Study on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Epstein-Barr Virus (EBV): A common virus that can cause infectious mononucleosis and is associated with certain cancers. It often leads to fatigue and other symptoms.
  • Asthenia: A medical term for weakness or lack of energy, often used to describe the fatigue associated with EBV infection.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Double-blind study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • CIS questionnaire: A tool used to assess various dimensions of fatigue in patients.
  • Lymphocytes typing: A test that identifies different types of white blood cells, which are important for immune function.
  • IgG: Immunoglobulin G, a type of antibody that plays a crucial role in immune response to infections.
  • Serology: The scientific study of blood serum, especially with regard to the response of the immune system to pathogens.
  • Homeopathic treatment: A form of alternative medicine based on the idea that substances that cause symptoms in healthy people can be used to treat similar symptoms in sick people.
  • Immunosuppressive treatment: Medication that suppresses or reduces the strength of the body's immune system.
  • Micro-immunotherapy: A type of immunotherapy that uses low doses of immune-regulating substances to modulate the immune system.
  • MFI-20 questionnaire: Multidimensional Fatigue Inventory, a 20-item self-report instrument designed to measure fatigue.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lebv-and-2lxfs-for-reducing-fatigue-in-patients-with-epstein-barr-virus-infection/